FI118224B - Icke-splitsande varianter av gp350/220 - Google Patents
Icke-splitsande varianter av gp350/220 Download PDFInfo
- Publication number
- FI118224B FI118224B FI964186A FI964186A FI118224B FI 118224 B FI118224 B FI 118224B FI 964186 A FI964186 A FI 964186A FI 964186 A FI964186 A FI 964186A FI 118224 B FI118224 B FI 118224B
- Authority
- FI
- Finland
- Prior art keywords
- thr
- pro
- ser
- sequence
- dna sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Detergent Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Polarising Elements (AREA)
- Paper (AREA)
Claims (20)
1. Isolerad DNA-sekvens, kännetecknad av att den kodar antingen EBV gp350-proteinen eller en trunkerad form av EBV gp350, ur vilken trunkerad form har avlägsnats en del av 5 eller hela membran skiljeytan, en del av eller hela membran skiljeytan och en del av eller hela kvarliggande karboxyländan och/eller en del av eller hela signalsekven-sen, vilken nämnd DNA-sekvens har modifierats för del av en eller flera splits-ningspunkter sä, att bildning av gp220 mRNA transkripten förhindras.
2. DNA-sekvens i enlighet med patentkrav 1, där DNA kodar trunkerade formen 10 av EVB gp350, av aminosyrar i vars membran skiljeytan minst 8 har avlägsnats.
3. DNA-sekvens i enlighet med patentkrav 2, som kodar trunkerade formen av EVB gp350, ur vilken aminosyrar mellan Met861-Ala88I har avlägsnats, som visas i figur 1 (SEQ ID. NO 18).
4. DNA-sekvens i enlighet med ett av föregäende patentkrav, i vilken DNA-15 sekvens nämnd transformation i en eller flera splitsningspunkter innefattar transformation i donors splitsningspunkt.
5. DNA-sekvens i enlighet med ett av föregäende patentkrav, i vilken DNA- sekvens nämnd transformation i en eller flera splitsningspunkter innefattar transsi.· formation i acceptors splitsningspunkt. • · • · · * I ·
6. DNA-sekvens i enlighet med patentkrav 5, där minst en nativ nukleotid, som ,:. kodar serin i kodon 501 av SEQ ID NO 18, har ersatts med en icke-nativ nukleotid och där minst en nativ nukleotid, som kodar glycin i kodon 698 av SEQ ID NO 18, har ersatts med en icke-nativ nukleotid. I « · * * ·
7. DNA-sekvens i enlighet med patentkrav 1, där DNA kodar samma aminosyre-25 sekvens, som har valts ur gruppen: »*· **"* a) kodons 19-862 av SEQ ID NO: 18 b) kodons 1-862 av SEQ ID NO: 18 c) kodons 19-862 och 882-907 av SEQ ID NO: 18; och d) kodons 1-862 och 882-907 av SEQ ID NO: 18 • · · * · ·**·· * · 118224
8. DNA-sekvens i enlighet med ett av föregäende patentkrav, i vilken DNA-sekvens transformation i en eller flera splitsningspunkter orsakar ingen förändring i aminosyresekvensen kodat av DNA-sekvensen.
9. DNA-sekvens i enlighet med ett av patentkrav 1-7, i vilken DNA-sekvens transformation i en eller flera splitsningspunkter orsakar förändring i aminosyrese-kvensen kodat av DNA-sekvensen.
10. DNA-sekvens i enlighet med patentkrav 9, i vilken DNA-sekvens förändring i aminosyresekvensen är konservativ.
11. Vektor, som innefattar DNA-sekvens i enlighet med ett av föregäende patent krav.
12. Värdcell, som har transformerats med DNA-sekvens i enlighet med ett av patentkrav 1-10 och som är operativt kopplad i sekvensen, som reglerar indikering och som kan styra replikering och indikering av den nämnda DNA-sekvensen, 15
13. Värdcell i enlighet med patentkrav 12 är en eukaryot cell.
14. Värdcell i enlighet med patentkrav 13 är en insekts- eller däggdjurscell.
15. Värdcell i enlighet med patentkrav 14 är en däggdjurscell.
: 16. Förfarande, där värdcell i enlighet med ett av patentkrav 12-15 odlas i lämplig • · · odligssubstrat och nämnd protein gp350 isoleras ffän nämnda cellen eller odlings- • · 20 substratet.
* ♦ ···:* 17. Förfarande i enlighet med patentkrav 16, där ytterligare den nämnda gp350- proteinen blandas i farmaceutiskt acceptabel bärare. • · ♦ * · · • ♦ ·
18. Farmaceutisk sammansättning, som innehäller en homogen, glykolyserad EBV gp350-protein i enlighet med ett av patentkrav 1-10, ur vilken protein en del • · · 25 av eller hela membran skiljeytan har avlägsnats, nämnd protein blandat i farmaceu- • · *·;*' tiskt acceptabel bärare, vilken sammansättning innehäller väsentligt ingen protein gP220. • · · - • · * «
19. Sammansättning i enlighet med patentkrav 18, där ocksä kvarliggande kar-boxylända av EBV gp350-proteinen har avlägsnats delvist eller helt. ♦ ···· • · 118224 5!
20. Sammansättning i enlighet med patentkrav 19, där aminosyrar 863-907 har avlägsnats frän EBV gp350-proteinen enligt figur 1 (SEQ ID NO 18). * »Il • 4 • * 4 • · • 4 · • » I • · * · • Ml 4 4444 • » » I • 4 · 4 · · 4 · « •*4.'' 4 4 4 4 44 ' 4 4 4 44 4 4 4 * 4 4. 4 4 *•4. 4 4 4 444 4*4. 4 4 * * 4 4 * 4 4 4 4 4 4 4 4 4 4' 4*4 4*4 • 4 4 4 4
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22929194A | 1994-04-18 | 1994-04-18 | |
| US22929194 | 1994-04-18 | ||
| PCT/US1995/004611 WO1995028488A1 (en) | 1994-04-18 | 1995-04-13 | NON-SPLICING VARIANTS OF gp350/220 |
| US9504611 | 1995-04-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI964186A0 FI964186A0 (sv) | 1996-10-18 |
| FI964186A FI964186A (sv) | 1996-12-17 |
| FI118224B true FI118224B (sv) | 2007-08-31 |
Family
ID=22860582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI964186A FI118224B (sv) | 1994-04-18 | 1996-10-18 | Icke-splitsande varianter av gp350/220 |
| FI20075338A FI20075338A (sv) | 1994-04-18 | 2007-05-10 | Icke-splitsande varianter av gb350/220 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20075338A FI20075338A (sv) | 1994-04-18 | 2007-05-10 | Icke-splitsande varianter av gb350/220 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6054130A (sv) |
| EP (1) | EP0769056B1 (sv) |
| JP (4) | JP3447743B2 (sv) |
| KR (1) | KR100380953B1 (sv) |
| CN (2) | CN1118573C (sv) |
| AT (1) | ATE210184T1 (sv) |
| AU (1) | AU707837B2 (sv) |
| BR (1) | BR9507473A (sv) |
| CA (1) | CA2187908C (sv) |
| CZ (1) | CZ292283B6 (sv) |
| DE (1) | DE69524415T2 (sv) |
| DK (1) | DK0769056T3 (sv) |
| ES (1) | ES2170144T3 (sv) |
| FI (2) | FI118224B (sv) |
| HU (1) | HU221647B1 (sv) |
| LV (1) | LV11803B (sv) |
| MY (1) | MY114769A (sv) |
| NO (1) | NO319382B1 (sv) |
| PL (1) | PL181881B1 (sv) |
| PT (1) | PT769056E (sv) |
| RU (1) | RU2178807C2 (sv) |
| SK (1) | SK283446B6 (sv) |
| TW (1) | TW496897B (sv) |
| UA (1) | UA47403C2 (sv) |
| WO (1) | WO1995028488A1 (sv) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6692749B1 (en) * | 1994-04-18 | 2004-02-17 | Medimmune Vaccines, Inc. | Non-splicing variants of gp350/220 |
| MY114769A (en) | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
| AU2582897A (en) * | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| AUPO784197A0 (en) * | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
| EP1036177A1 (en) * | 1997-12-05 | 2000-09-20 | The Immune Response Corporation | Novel vectors and genes exhibiting increased expression |
| AU762799B2 (en) | 1998-06-12 | 2003-07-03 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220 |
| GB0210682D0 (en) * | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
| EP2432793A4 (en) * | 2009-05-22 | 2012-11-28 | Intelligent Med Devices Inc | OPTIMIZED PROBES AND PRIMERS, AND METHOD FOR USING THEM TO DETECT, SCREEN, QUANTIFY, INSOLATE, AND SEQUENCY THE CYTOMEGALOVIRUS AND EPSTEIN BARR VIRUS |
| US10461635B1 (en) * | 2018-05-15 | 2019-10-29 | Analog Devices Global Unlimited Company | Low VIN high efficiency chargepump |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3069310D1 (en) * | 1980-11-03 | 1984-10-31 | Itt Ind Gmbh Deutsche | Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage |
| US4707358A (en) * | 1984-01-30 | 1987-11-17 | The University Of Chicago | Vaccine against Epstein-Barr Virus |
| US5244792A (en) * | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
| US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| DE3583564D1 (de) * | 1984-08-23 | 1991-08-29 | Hans Joachim Wolf | Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. |
| EP0312164A1 (en) * | 1987-10-16 | 1989-04-19 | Merck & Co. Inc. | Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells |
| CA2090295A1 (en) * | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
| WO1993019092A1 (fr) * | 1992-03-19 | 1993-09-30 | Centre National De La Recherche Scientifique | Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr |
| US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| MY114769A (en) | 1994-04-18 | 2003-01-31 | Aviron Inc | Non-splicing variants of gp350/220 |
-
1995
- 1995-04-06 MY MYPI95000884A patent/MY114769A/en unknown
- 1995-04-13 CA CA002187908A patent/CA2187908C/en not_active Expired - Lifetime
- 1995-04-13 CN CN95193673A patent/CN1118573C/zh not_active Expired - Lifetime
- 1995-04-13 DE DE69524415T patent/DE69524415T2/de not_active Expired - Lifetime
- 1995-04-13 RU RU96122169/13A patent/RU2178807C2/ru not_active IP Right Cessation
- 1995-04-13 SK SK1343-96A patent/SK283446B6/sk not_active IP Right Cessation
- 1995-04-13 AT AT95916984T patent/ATE210184T1/de active
- 1995-04-13 PL PL95316941A patent/PL181881B1/pl not_active IP Right Cessation
- 1995-04-13 UA UA96114355A patent/UA47403C2/uk unknown
- 1995-04-13 AU AU23838/95A patent/AU707837B2/en not_active Expired
- 1995-04-13 PT PT95916984T patent/PT769056E/pt unknown
- 1995-04-13 BR BR9507473A patent/BR9507473A/pt not_active IP Right Cessation
- 1995-04-13 WO PCT/US1995/004611 patent/WO1995028488A1/en active Application Filing
- 1995-04-13 HU HU9602894A patent/HU221647B1/hu not_active IP Right Cessation
- 1995-04-13 CZ CZ19963054A patent/CZ292283B6/cs not_active IP Right Cessation
- 1995-04-13 EP EP95916984A patent/EP0769056B1/en not_active Expired - Lifetime
- 1995-04-13 CN CNB031454984A patent/CN100415895C/zh not_active Expired - Lifetime
- 1995-04-13 KR KR1019960705822A patent/KR100380953B1/ko not_active IP Right Cessation
- 1995-04-13 DK DK95916984T patent/DK0769056T3/da active
- 1995-04-13 ES ES95916984T patent/ES2170144T3/es not_active Expired - Lifetime
- 1995-04-13 JP JP52710995A patent/JP3447743B2/ja not_active Expired - Lifetime
- 1995-09-13 TW TW084109561A patent/TW496897B/zh not_active IP Right Cessation
-
1996
- 1996-10-18 FI FI964186A patent/FI118224B/sv not_active IP Right Cessation
- 1996-10-18 NO NO19964431A patent/NO319382B1/no not_active IP Right Cessation
- 1996-11-12 LV LVP-96-430A patent/LV11803B/en unknown
-
1997
- 1997-01-15 US US08/783,774 patent/US6054130A/en not_active Expired - Lifetime
- 1997-08-25 US US08/917,320 patent/US5824508A/en not_active Expired - Lifetime
-
2000
- 2000-04-24 US US09/556,706 patent/US6458364B1/en not_active Expired - Lifetime
-
2003
- 2003-02-26 JP JP2003049908A patent/JP2003230396A/ja not_active Withdrawn
-
2004
- 2004-05-19 JP JP2004149099A patent/JP4317786B2/ja not_active Expired - Lifetime
-
2005
- 2005-06-15 JP JP2005175699A patent/JP2005333990A/ja active Pending
-
2007
- 2007-05-10 FI FI20075338A patent/FI20075338A/sv not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells | |
| Yaswen et al. | Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein | |
| Jackman et al. | Expression of Epstein–Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine | |
| JP2607712B2 (ja) | 組換えｃｍｖ中和タンパク | |
| Liu et al. | T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice | |
| IE58030B1 (en) | Vaccines based on membrane bound proteins and process for making them | |
| Lake et al. | The Epstein-Barr virus (EBV) gN homolog BLRF1 encodes a 15-kilodalton glycoprotein that cannot be authentically processed unless it is coexpressed with the EBV gM homolog BBRF3 | |
| JP2005333990A (ja) | ｇｐ３５０／２２０非スプライシング変異体 | |
| EP0208672A1 (en) | Vaccines and diagnostics derived from bovine diarrhea virus | |
| US5807557A (en) | Soluble herpesvirus glycoprotein complex | |
| US20130064844A1 (en) | Non-splicing variants of gp350/220 | |
| Guo et al. | Characterization of a structurally tricistronic gene of human cytomegalovirus composed of U (s) 18, U (s) 19, and U (s) 20 | |
| WO1998015289A9 (en) | Proteins of kaposi's sarcoma associated herpesvirus | |
| WO1995029991A1 (en) | A novel vzv gene, mutant vzv and immunogenic compositions | |
| JP2883085B2 (ja) | Ｈｃｍｖの糖タンパク質類、それらに対する抗体類及びｈｃｍｖワクチンの産生法、並びにそれらのための組換えベクター | |
| CA2156719A1 (en) | Recombinant epstein-barr virus protein and its use in vaccine | |
| Heineman | The Mapping of Epstein-Barr Virus Gp85 and the Identification of a Novel EBV Glycoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118224 Country of ref document: FI |
|
| MM | Patent lapsed |